全文获取类型
收费全文 | 29259篇 |
免费 | 2006篇 |
国内免费 | 326篇 |
专业分类
耳鼻咽喉 | 549篇 |
儿科学 | 449篇 |
妇产科学 | 390篇 |
基础医学 | 4730篇 |
口腔科学 | 872篇 |
临床医学 | 2625篇 |
内科学 | 5792篇 |
皮肤病学 | 1070篇 |
神经病学 | 2125篇 |
特种医学 | 1834篇 |
外科学 | 3534篇 |
综合类 | 238篇 |
现状与发展 | 3篇 |
一般理论 | 8篇 |
预防医学 | 1202篇 |
眼科学 | 506篇 |
药学 | 2714篇 |
中国医学 | 428篇 |
肿瘤学 | 2522篇 |
出版年
2023年 | 226篇 |
2022年 | 745篇 |
2021年 | 1111篇 |
2020年 | 608篇 |
2019年 | 813篇 |
2018年 | 963篇 |
2017年 | 791篇 |
2016年 | 1140篇 |
2015年 | 1529篇 |
2014年 | 1636篇 |
2013年 | 1946篇 |
2012年 | 2717篇 |
2011年 | 2514篇 |
2010年 | 1577篇 |
2009年 | 1256篇 |
2008年 | 1676篇 |
2007年 | 1517篇 |
2006年 | 1279篇 |
2005年 | 1196篇 |
2004年 | 955篇 |
2003年 | 835篇 |
2002年 | 685篇 |
2001年 | 433篇 |
2000年 | 402篇 |
1999年 | 327篇 |
1998年 | 220篇 |
1997年 | 189篇 |
1996年 | 143篇 |
1995年 | 118篇 |
1994年 | 116篇 |
1993年 | 106篇 |
1992年 | 122篇 |
1991年 | 135篇 |
1990年 | 127篇 |
1989年 | 118篇 |
1988年 | 113篇 |
1987年 | 89篇 |
1986年 | 97篇 |
1985年 | 79篇 |
1984年 | 51篇 |
1983年 | 50篇 |
1982年 | 35篇 |
1979年 | 57篇 |
1978年 | 43篇 |
1976年 | 32篇 |
1975年 | 61篇 |
1972年 | 39篇 |
1971年 | 49篇 |
1970年 | 34篇 |
1968年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Macrophage migration inhibitory factor (MIF) is a cytokine that mediates the interaction between malignant cells and the innate immune system. Recently, MIF has received attention for its role in tumorigenesis. We evaluated the prognostic role of MIF in clear cell renal cell carcinoma (CCRCC).A total of 152 patients, who underwent nephrectomy for CCRCC were enrolled in this study. Immunohistochemical staining of tissue microarray blocks containing 298 cores—2 cores per CCRCC patient was performed. The relationship between MIF expression and clinicopathological factors was evaluated. Total RNA and protein were extracted from 7 RCC (renal cell carcinoma) cell lines. MIF was knocked down in Caki-2 cells, and a wound healing assay was performed to evaluate migratory activity.Among the 298 cores, 180 (60.4%) were positive for MIF. Multivariate analysis, showed that, CCRCC patients with negative MIF expression exhibited poor disease-free survival (hazard ratio: 2.087, 95% confidence interval: 0.821–5.307, P value: .023) and poor disease-specific survival (hazard ratio: 2.101, 95% confidence interval: 1.009–4.374, P value: .047). The wound healing assay revealed that cell confluence was lower in MIF-deficient Caki-2 cells than in control cells.Negative MIF expression might be an independent prognostic marker for patients with CCRCC. 相似文献
992.
Yuna Seo Han-Gyul Lee Chul Jin Seung-bo Yang Seung-Yeon Cho Seong-Uk Park Woo-Sang Jung Sang-Kwan Moon Jung-Mi Park Chang-Nam Ko Ki-Ho Cho Seungwon Kwon 《Medicine》2020,99(50)
Background:Despite the rapid advances in medical technology, including endovascular interventions and medications, cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) is still one of the major threats to the lives of patients with SAH. In East Asian countries, various types of herbal medicines have been used to treat cerebrovascular diseases, including SAH. In this review, we aim to evaluate the efficacy and safety of herbal medicines for the prevention and treatment of CVS after SAH.Methods and analysis:Seven databases will be searched for relevant studies from inception to the present date “June 2020”. Only randomized controlled trials (RCTs) that assess the effect and safety of herbal medicines for the prevention and treatment of CVS after SAH will be included. The methodological quality will be evaluated using the Cochrane risk of bias assessment tool. After selecting the appropriate studies, a meta-analysis of the RCTs will be performed.Results:This study will provide a high-quality synthesis of current evidence of herbal medicines for CVS after SAH.Conclusion:Our systematic review will provide evidence to judge whether herbal medicines are effective interventions for patients with CVS after SAH.Ethics and dissemination:Ethical approval is not required, as this study is based on a review of published research. This review will be published in a peer-reviewed journal and disseminated electronically and in print.Trial registration number:Research registry reviewregistry923. 相似文献
993.
994.
995.
996.
Hongryeol Park Hyei Yoon Jung Hyun-Jung Choi Dong Young Kim Ji-Young Yoo Chae-Ok Yun Jeong-Ki Min Young-Myoung Kim Young-Guen Kwon 《Angiogenesis》2014,17(1):221-234
Tumor angiogenesis is essential for tumor invasive growth and metastasis, and generates abnormal vascular structures unlike developmental neovessel formation. To reduce tumor vascular abnormalities such as leakage and perivascular cell coverage deficiency that limit cancer therapy effectiveness, novel therapeutic approaches focus on vessel normalization. We have previously shown that Dickkopf-1 (DKK1), a Wnt antagonist, inhibits and its homolog DKK2 enhances, angiogenesis in normal tissues. In the present study, we investigated the effects of DKK1 and DKK2 on tumor growth and angiogenesis. Treatment of B16F10 melanoma-bearing mice with adenovirus expressing DKK1 significantly reduced tumor growth but DKK2 increased growth compared with controls. Similar pattern of tumor growth was observed in endothelial-specific DKK1 and DKK2 transgenic mice. Interestingly, tumor vascular density and perfusion were significantly decreased by DKK1 but increased by DKK2. Moreover, coverage of blood vessels by pericytes was reduced by DKK1, while DKK2 increased it. We further observed that DKK1 diminished retinal vessel density and increased avascular area in an in vivo murine model of oxygen-induced retinopathy, whereas DKK2 showed opposite results. These findings demonstrate that DKK1 and DKK2 have differential roles in normalization and functionality of tumor blood vessels, in addition to angiogenesis. 相似文献
997.
Park Chae Jung Han Kyunghwa Shin Haesol Ahn Sung Soo Choi Yoon Seong Park Yae Won Chang Jong Hee Kim Se Hoon Jain Rajan Lee Seung-Koo 《European radiology》2020,30(6):3035-3045
European Radiology - To identify significant prognostic magnetic resonance imaging (MRI) features and their prognostic value when added to clinical features in patients with isocitrate... 相似文献
998.
999.
Lisa G. Suter MD Shu-Xia Li PhD Jacqueline N. Grady MS Zhenqiu Lin PhD Yongfei Wang MS Kanchana R. Bhat MPH Dima Turkmani DrPH MBA Steven B. Spivack MPH Peter K. Lindenauer MD MSc Angela R. Merrill PhD Elizabeth E. Drye MD SM Harlan M. Krumholz MD SM Susannah M. Bernheim MD MHS 《Journal of general internal medicine》2014,29(10):1333-1340
BACKGROUND
The Centers for Medicare & Medicaid Services publicly reports risk-standardized mortality rates (RSMRs) within 30-days of admission and, in 2013, risk-standardized unplanned readmission rates (RSRRs) within 30-days of discharge for patients hospitalized with acute myocardial infarction (AMI), heart failure (HF), and pneumonia. Current publicly reported data do not focus on variation in national results or annual changes.OBJECTIVE
Describe U.S. hospital performance on AMI, HF, and pneumonia mortality and updated readmission measures to provide perspective on national performance variation.DESIGN
To identify recent changes and variation in national hospital-level mortality and readmission for AMI, HF, and pneumonia, we performed cross-sectional panel analyses of national hospital performance on publicly reported measures.PARTICIPANTS
Fee-for-service Medicare and Veterans Health Administration beneficiaries, 65 years or older, hospitalized with principal discharge diagnoses of AMI, HF, or pneumonia between July 2009 and June 2012. RSMRs/RSRRs were calculated using hierarchical logistic models risk-adjusted for age, sex, comorbidities, and patients’ clustering among hospitals.Results
Median (range) RSMRs for AMI, HF, and pneumonia were 15.1% (9.4–21.0%), 11.3% (6.4–17.9%), and 11.4% (6.5–24.5%), respectively. Median (range) RSRRs for AMI, HF, and pneumonia were 18.2% (14.4–24.3%), 22.9% (17.1–30.7%), and 17.5% (13.6–24.0%), respectively. Median RSMRs declined for AMI (15.5% in 2009–2010, 15.4% in 2010–2011, 14.7% in 2011–2012) and remained similar for HF (11.5% in 2009–2010, 11.9% in 2010–2011, 11.7% in 2011–2012) and pneumonia (11.8% in 2009–2010, 11.9% in 2010–2011, 11.6% in 2011–2012). Median hospital-level RSRRs declined: AMI (18.5% in 2009–2010, 18.5% in 2010–2011, 17.7% in 2011–2012), HF (23.3% in 2009–2010, 23.1% in 2010–2011, 22.5% in 2011–2012), and pneumonia (17.7% in 2009–2010, 17.6% in 2010–2011, 17.3% in 2011–2012).Conclusions
We report the first national unplanned readmission results demonstrating declining rates for all three conditions between 2009–2012. Simultaneously, AMI mortality continued to decline, pneumonia mortality was stable, and HF mortality experienced a small increase. 相似文献1000.
Holly C. Gooding MD MS Shannon McGinty MD Tracy K. Richmond MD MPH Matthew W. Gillman MD SM Alison E. Field ScD 《Journal of general internal medicine》2014,29(8):1098-1104